Focus on best combination of validated targets and ADC technology to tackle hard to treat cancers
Duisburg, Germany – Marseille, France, 1 October 2019: Emergence Therapeutics AG today announced its incorporation by founders Jack Elands, Xavier Preville and Kurma Partners. Emergence Therapeutics is a new pan-European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high unmet need cancers. The company is based in Duisburg, Germany with a subsidiary in Marseille, France.
Dr. Jack Elands, Chief Executive Officer commented: “Recent developments show that ADC technology is maturing. ADCs now represent a significant opportunity to treat solid cancers of high unmet medical need. Emergence Therapeutics’ strategy is to develop novel ADCs to treat such cancers by selecting the best combination of validated targets and ADC technology. The company is completing the process of in-licensing key assets to embark on its first program.”
Dr. Peter Neubeck, investment director at Kurma partners added: “As an investor in early-stage opportunities Kurma is proud to be a co-founder of Emergence Therapeutics and help the company to secure further investments towards its goal of developing novel ADCs.”